On February 27, 2017 Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, reported an oral presentation for its lead product candidate, tipifarnib, at the 15th International Congress on Targeted Anticancer Therapies (TAT 2017), taking place March 6-8, 2017 in Paris, France (Press release, Kura Oncology, FEB 27, 2017, View Source [SID1234517845]). The presentation will feature clinical data from the first stage of Kura Oncology’s tipifarnib Phase 2 program in HRAS mutant tumors. Schedule your 30 min Free 1stOncology Demo! Presentation:
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date & Time: March 6, 2017, 2:45 p.m. – 3:00 p.m. CET
Title of Presentation: Preliminary evidence of clinical activity with tipifarnib in squamous cell carcinomas of the head & neck (SCCHN) with HRAS mutations
Presenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
Session: Plenary Session 3: Phase 1 Studies – Completed or in progress (miscellaneous drugs & targets)